NAS:ESPR (USA) Also trade in: Germany UK

Esperion Therapeutics Inc

$ 51.57 0 (0%)
Volume: 786,425 Avg Vol (1m): 638,907
Market Cap $: 1.39 Bil Enterprise Value $: 1.16 Bil
P/E (TTM): 0.00 P/B: 8.39
Earnings Power Value 10.41
Net Current Asset Value 6.11
Tangible Book 6.15
Projected FCF -13.1
Median P/S Value 43.9
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
55.38% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
ESPR: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.23, Med: 46.06, Max: 10000
Current: 10000
0.23
10000
Equity-to-Asset 0.74
Equity-to-Asset ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
ESPR: 0.74
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.72, Med: 0.83, Max: 0.88
Current: 0.74
0.72
0.88
Interest Coverage No Debt
Interest Coverage ranked lower than
100.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
ESPR: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 11.12
DISTRESS
GREY
SAFE
Beneish M-Score 129317.10
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 0%
WACC 13.15%

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -48.66
Operating Margin ranked lower than
100.00% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
ESPR: -48.66
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -48.66, Med: 0, Max: 0
Current: -48.66
-48.66
0
Net Margin % -46.97
Net Margin ranked lower than
100.00% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
ESPR: -46.97
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -46.97, Med: 0, Max: 0
Current: -46.97
-46.97
0
ROE % -44.01
ROE ranked lower than
68.25% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
ESPR: -44.01
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -248.35, Med: -54.59, Max: -23.66
Current: -44.01
-248.35
-23.66
ROA % -33.84
ROA ranked lower than
75.28% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
ESPR: -33.84
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -247.41, Med: -42.33, Max: -22.69
Current: -33.84
-247.41
-22.69
ROC (Joel Greenblatt) % -15887.29
ROC (Joel Greenblatt) ranked lower than
93.92% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
ESPR: -15887.29
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -42845.03, Med: -7297.6, Max: -629.57
Current: -15887.29
-42845.03
-629.57
3-Year Total EBITDA Growth Rate -60.90
3-Year EBITDA Growth Rate ranked lower than
86.41% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
ESPR: -50.8
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -62.8, Med: -1.9, Max: 57.7
Current: -50.8
-62.8
57.7
3-Year EPS w/o NRI Growth Rate -49.40
3-Year EPS w/o NRI Growth Rate ranked lower than
89.65% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
ESPR: -49.4
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
N/A

» ESPR's 30-Y Financials

Financials (Next Earnings Date: 2019-08-02)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:ESPR

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare SZSE:300149 NAS:AUTL SZSE:000403 NAS:IFRX NAS:EPZM XKRX:298380 NAS:ALDR NAS:FATE NAS:GOSS XMAD:ROVI SZSE:300204 NAS:PBYI SZSE:002275 SZSE:300255 NAS:APLS NAS:CHRS NYSE:MYOV NAS:SPPI NAS:AIMT NAS:EDIT
Traded in other countries 0ET.Germany 0IIM.UK
Address 3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.

Ratios

Current vs industry vs history
PB Ratio 8.39
PB Ratio ranked lower than
69.44% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
ESPR: 8.39
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 6.53, Med: 7.14, Max: 8.52
Current: 8.39
6.53
8.52
PS Ratio 10.08
PS Ratio ranked lower than
100.00% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
ESPR: 10.08
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 7.86, Med: 8.59, Max: 10.25
Current: 10.08
7.86
10.25
EV-to-EBIT -16.39
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
ESPR: -16.39
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -17.6, Med: -14.45, Max: -12.9
Current: -16.39
-17.6
-12.9
EV-to-EBITDA -16.45
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
ESPR: -16.45
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -17.6, Med: -14.45, Max: -13
Current: -16.45
-17.6
-13
EV-to-Revenue 7.94
EV-to-Revenue ranked lower than
100.00% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
ESPR: 7.94
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 6.3, Med: 7, Max: 8.5
Current: 7.94
6.3
8.5
Current Ratio 3.92
Current Ratio ranked higher than
57.26% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
ESPR: 3.92
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.42, Med: 9.9, Max: 40.33
Current: 3.92
0.42
40.33
Quick Ratio 3.92
Quick Ratio ranked higher than
59.03% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
ESPR: 3.92
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.42, Med: 9.9, Max: 40.33
Current: 3.92
0.42
40.33

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -5.90
3-Year Share Buyback Rate ranked higher than
64.18% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
ESPR: -5.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -288.8, Med: -15.6, Max: 54.6
Current: -5.9
-288.8
54.6

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 8.39
Price-to-Tangible-Book ranked lower than
62.19% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
ESPR: 8.39
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 0.83, Med: 4.71, Max: 15.6
Current: 8.39
0.83
15.6
Price-to-Median-PS-Value 1.17
Price-to-Median-PS-Value ranked lower than
100.00% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
ESPR: 1.17
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.93, Med: 0.93, Max: 1.19
Current: 1.17
0.93
1.19
Earnings Yield (Joel Greenblatt) % -6.13
Earnings Yield (Greenblatt) ranked lower than
66.42% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
ESPR: -6.13
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -7.7, Med: -6.95, Max: -5.7
Current: -6.13
-7.7
-5.7

More Statistics

Revenue (TTM) (Mil) $ 145.42
EPS (TTM) $ -2.74
Beta 1.79
Volatility % 58.04
52-Week Range $ 35.8 - 60.99
Shares Outstanding (Mil) 26.92

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y